This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.
FDA approves topical Mirvaso® for facial erythema of rosacea
Galderma Laboratories, L.P. has announced that the US Food and Drug Administration (FDA) has approved Mirvaso® (brimonidine) topical gel, 0.33% for the topical treatment of the facial erythema (redness) of
